Responding to the Market in Preparation for an 80% Generic Volume Share
First written in FY2017-Q1. 14 of 16 entries say "Restated". Latest entry: FY2025-H1.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2024.
0 other companies' latest entry also says "Worsened".
- FY2025-H1WorsenedAnnual report
「During the current interim consolidated accounting period, Japan’s prescription pharmaceutical industry faced an increasingly challenging environment due to the continued promotion of measures to contain healthcare costs, including the drug-price revision implemented in April 2024, and the prescription pharmaceutical market’s growth rate remained flat.」
The domestic prescription pharmaceutical market was described as facing an increasingly challenging environment due to the April 2024 drug-price revision and continuing measures to contain healthcare costs, with the growth rate remaining flat. - FY2024-Q3RestatedAnnual report
「During the first 3 quarters of the current consolidated fiscal year, Japan’s prescription pharmaceutical industry saw the interim-year drug-price revision implemented in April 2023. However, as COVID-19 was reclassified under the Infectious Diseases Act as a Category 5 infectious disease, patients’ medical consultation behavior recovered to pre-pandemic levels, and the prescription pharmaceutical market grew at a low single-digit rate.」
The situation in Japan’s pharmaceutical market, where the interim-year drug-price revision coincided with a recovery in medical consultation behavior, continues to be described. - FY2024-Q2RestatedAnnual report
「The environment surrounding Japan’s prescription pharmaceutical business is becoming increasingly challenging due to continuing drug-price revisions and other measures aimed at containing drug costs.」
The challenging business environment for Japan’s pharmaceutical business resulting from drug-price revisions and other measures to contain drug costs continues to be described. - FY2022-Q3RestatedAnnual report
「The environment surrounding Japan’s prescription pharmaceutical business is becoming increasingly challenging due to continuing measures to contain drug costs.」
The challenging business environment for Japan’s pharmaceutical business resulting from measures to contain drug costs continues to be described. - FY2022-Q2RestatedAnnual report
「The environment surrounding Japan’s prescription pharmaceutical business is becoming increasingly challenging due to continuing measures to contain drug costs.」
The challenging business environment for Japan’s pharmaceutical business resulting from measures to contain drug costs and drug-price revisions continues to be described. - FY2021-Q3RestatedAnnual report
「During the period under review, Japan’s pharmaceutical industry continued to face a challenging business environment due to the implementation of drug-price revisions following the consumption-tax increase (October 2019; industry average: 2.40%), drug-price revisions in line with reforms to the drug-pricing system (April 2020; industry average: 4.38%), and the spread of COVID-19.」
The challenging business environment for Japan’s pharmaceutical industry continued due to drug-price revisions and the spread of COVID-19. - FY2021-Q2RestatedAnnual report
「During the period under review, Japan’s pharmaceutical industry remained at a low level due to the implementation of drug-price revisions following the consumption-tax increase (October 2019; industry average: 2.40%), drug-price revisions in line with reforms to the drug-pricing system (April 2020; industry average: 4.38%), and reduced medical consultations resulting from the spread of COVID-19.」
The situation in which reduced medical consultations resulting from COVID-19 were added to the challenging market environment caused by drug-price revisions and measures to promote the use of generic drugs continues to be described. - FY2020-Q1RestatedAnnual report
「The environment remained challenging due to policies to contain drug costs, including fundamental reforms to the drug-pricing system and measures to promote the use of generic drugs, and the market remained sluggish.」
The challenging market environment resulting from policies to contain drug costs and promote the use of generic drugs continues to be described. - FY2019RestatedAnnual report
「In addition, as the era of generic drugs accounting for 80% of volume approaches,」
The era of generic drugs accounting for 80% of volume continues to be described as part of the business environment. - FY2019-Q3RestatedAnnual report
「In addition, as the era of generic drugs accounting for 80% of volume approaches,」
The era of generic drugs accounting for 80% of volume continues to be described as part of the business environment. - FY2019-Q2RestatedAnnual report
「In addition, as the era of generic drugs accounting for 80% of volume approaches,」
The era of generic drugs accounting for 80% of volume continues to be described as part of the business environment. - FY2018RestatedAnnual report
「In recent years, the external environment surrounding the prescription pharmaceutical business has been expected to undergo changes in market structure due to the arrival of the era of 80% generics and reforms to the drug-pricing system,」
The arrival of the era of 80% generics continues to be described as part of the external environment for the prescription pharmaceutical business. - FY2017RestatedAnnual report
「As measures to promote the use of generic drugs are implemented to achieve the government’s target of an 80% volume share for generic drugs,」
The government’s 80% volume-share target for generic drugs continues to be described as part of the business environment. - FY2017-Q3RestatedAnnual report
「As measures to promote the use of generic drugs are implemented to achieve the government’s target of an 80% volume share for generic drugs,」
The government’s 80% volume-share target for generic drugs continues to be described as part of the business environment. - FY2017-Q2RestatedAnnual report
「As the government implements further measures to promote generic use in pursuit of its target of an 80% volume share for generic pharmaceuticals,」
The government’s 80% volume-share target for generic drugs continues to be described as part of the business environment. - FY2017-Q1First statedAnnual report
「As the government implements further measures to promote generic use in pursuit of its target of an 80% volume share for generic pharmaceuticals,」
The government’s 80% target for generic volume share and measures to promote generic use are described as part of the business environment.